Scholarlink

Background <p>Proprotein convertase subtilisin kexin/type-9 (PCSK-9) regulates cholesterol homeostasis through lysosomal degradation of LDL-R and also acts as a pleiotropic mediator of inflammation. Emerging evidence links PCSK-9 to diabetes pathogenesis. Given the genetic diversity and distinct lifestyle of the Indian population, investigating role of PCSK-9 in Indian type-2 diabetes mellitus (T2DM) patients is crucial. Notably, its association with ApoCIII and chemokines such as CXCL2 and MCP-1 remains unexplored.</p> Results <p>A total of 187 participants were included: Heathy control (HC; <i>n</i> = 50), T2DM (<i>n</i> = 49), T2DM with nephropathy (T2DM-N; <i>n</i> = 43), and T2DM with dyslipidaemia (T2DM-DL; <i>n</i> = 45). Plasma PCSK-9, apolipoprotein CIII (ApoCIII), C-X-C motif chemokine ligand 2 (CXCL2), and Monocyte chemoattractant protein-1 (MCP-1) levels were quantified using ELISA. PCSK-9, ApoCIII, CXCL2, and MCP-1 were significantly elevated among diabetic groups when compared to HC subjects. A significant correlation was observed between PCSK-9 and higher levels of ApoCIII, CXCL2, and MCP-1, whereas no such association was observed in HC. Moreover, receiver operating characteristics (ROC) curve analysis demonstrated diagnostic accuracy of the studied biomarkers for predicting diabetes. PCSK-9 showed an area under curve (AUC) of 0.9863 (sensitivity 97%, specificity 100%), CXCL-2 an AUC of 0.9841 (sensitivity 92%, specificity 100%), ApoCIII an AUC of 0.9598 (sensitivity 84%, specificity 96%), and MCP-1 an AUC of 1.00 (sensitivity 100%, specificity 100%).</p> Conclusion <p>Elevated PCSK-9 levels showed significant association with ApoCIII, CXCL2, and MCP-1, suggesting a possible interplay between lipid metabolic and inflammatory pathways in T2DM. This study opens new avenues for utilizing PCSK-9 as a non-traditional biomarker in chronic diabetes management, risk stratification, treatment optimization, and personalized medicine. However, to generalize these findings, larger cohorts and multicentric studies are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic significance and interplay of circulatory PCSK-9–ApoCIII–chemokine axis in type 2 diabetes and its complications: a pilot study in North Indian patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月13日

查看全文
  • Mohd Waiz,
  • Sahir Sultan Alvi,
  • Parvej Ahmad,
  • Bodor Bin Sheeha,
  • Paridhi Puri,
  • Irfan Ahmad,
  • Saheem Ahmad,
  • M. Salman Khan

摘要

Background

Proprotein convertase subtilisin kexin/type-9 (PCSK-9) regulates cholesterol homeostasis through lysosomal degradation of LDL-R and also acts as a pleiotropic mediator of inflammation. Emerging evidence links PCSK-9 to diabetes pathogenesis. Given the genetic diversity and distinct lifestyle of the Indian population, investigating role of PCSK-9 in Indian type-2 diabetes mellitus (T2DM) patients is crucial. Notably, its association with ApoCIII and chemokines such as CXCL2 and MCP-1 remains unexplored.

Results

A total of 187 participants were included: Heathy control (HC; n = 50), T2DM (n = 49), T2DM with nephropathy (T2DM-N; n = 43), and T2DM with dyslipidaemia (T2DM-DL; n = 45). Plasma PCSK-9, apolipoprotein CIII (ApoCIII), C-X-C motif chemokine ligand 2 (CXCL2), and Monocyte chemoattractant protein-1 (MCP-1) levels were quantified using ELISA. PCSK-9, ApoCIII, CXCL2, and MCP-1 were significantly elevated among diabetic groups when compared to HC subjects. A significant correlation was observed between PCSK-9 and higher levels of ApoCIII, CXCL2, and MCP-1, whereas no such association was observed in HC. Moreover, receiver operating characteristics (ROC) curve analysis demonstrated diagnostic accuracy of the studied biomarkers for predicting diabetes. PCSK-9 showed an area under curve (AUC) of 0.9863 (sensitivity 97%, specificity 100%), CXCL-2 an AUC of 0.9841 (sensitivity 92%, specificity 100%), ApoCIII an AUC of 0.9598 (sensitivity 84%, specificity 96%), and MCP-1 an AUC of 1.00 (sensitivity 100%, specificity 100%).

Conclusion

Elevated PCSK-9 levels showed significant association with ApoCIII, CXCL2, and MCP-1, suggesting a possible interplay between lipid metabolic and inflammatory pathways in T2DM. This study opens new avenues for utilizing PCSK-9 as a non-traditional biomarker in chronic diabetes management, risk stratification, treatment optimization, and personalized medicine. However, to generalize these findings, larger cohorts and multicentric studies are warranted.